Vanguard Global Advisers
AKBA icon

Vanguard Global Advisers’s Akebia Therapeutics AKBA Stock Holding History

Vanguard Global Advisers’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$251K Buy
220,561
+118,416
+116% +$141K ﹤0.01% 2410
2026
Q1 		$142K Buy
+102,145
New +$140K ﹤0.01% 2581

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Global Advisers's AKBA Position: Q2 2026 in Review

Vanguard Global Advisers increased its Akebia Therapeutics (AKBA) stake by 116% in Q2 2026, buying an estimated $141K and bringing the position to 220,561 shares worth $251K. The position accounts for ﹤0.01% of the portfolio, ranked #2410.

Vanguard Global Advisers first reported a position in AKBA in Q1 2026 and has held it in 2 quarters since. 168 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Vanguard Global Advisers held 220,561 shares of Akebia Therapeutics worth $251K as of Q2 2026.
  • Vanguard Global Advisers bought 118,416 Akebia Therapeutics shares in Q2 2026, an estimated $141K.
  • Akebia Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2410 holding.
  • Vanguard Global Advisers first reported a position in Akebia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 168 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.